Updates on Generation of Patient-Derived iPSCs June 03, 2026

Patient-derived induced pluripotent stem cells (iPSCs) are an important tool for studying rare diseases and developing new therapies. Previously, MAODF had an iPSC line generated from a MAO-A/B patient and an iPSC line from a healthy parent as control. These cell lines have been successfully differentiated into nerve cells and are being used in ongoing MAOD research.

To expand its research capabilities, MAODF have decided to generate nine additional patient-derived iPSC lines, including four from individuals with combined MAO-A/B deficiency and five from individuals with MAO-A deficiency. iPSCs will be generated from blood and stored at the Coriell Institute for Medical Research in New Jersey.

These cell lines can be differentiated into neurons, brain organoids and other specialized cell types to model MAOD in the laboratory. They will support studies of disease mechanisms, drug screening, evaluation of treatment responses, and testing of emerging gene and RNA-based therapies. This expanded iPSC resource will help accelerate the development of potential treatments for individuals affected by MAOD.